Friday, April 26, 2013

TSX-V listed company receives U.S. patents for leading cancer drug candidate

Critical Outcome Technologies Inc. announced today that the United States Patent and Trademark Office has granted two patents for the Company’s leading cancer drug candidate. The preclinical drug compound known as COTI-2 represents a potentially dramatic change in the treatment of cancers with mutations of the p53 gene, found in more than 50% off all human cancers.
"These additional patents provide further support for developing COTI‐2 as an exciting new cancer therapy," said Dr. Wayne Danter, President and CEO of COTI. "The continued strengthening of our patent position is consistent with our extensive pre‐clinical evaluation of the drug. We believe it is only a matter of time before the world recognizes the importance of COTI‐2 to cancer treatment and a partner comes forward to take this drug to the clinic."
Here is a link to the Company's news release:

No comments:

Post a Comment